<DOC>
	<DOCNO>NCT00811759</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving sorafenib together temozolomide may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose give sorafenib together temozolomide treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Sorafenib Temozolomide Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety profile maximum tolerate dose sorafenib tosylate temozolomide patient stage III-IV melanoma . ( Phase I ) - Evaluate progression-free survival 12 week . ( Phase II ) Secondary - Evaluate tumor response accord RECIST criterion . - Evaluate overall progression-free survival . - Evaluate effect treatment tumor vascularization . - Compare pharmacokinetic profile temozolomide without sorafenib tosylate . - Evaluate number role lymphocyte . - Correlate tumor response rate BRAF mutation status . - Correlate response rate MGMT activity . - Compare efficacy genomics proteomics mean discovery serum biomarkers . - Study prognostic predictive value circulate endothelial cell circulate endothelial progenitor . OUTLINE : This phase I dose-escalation study follow phase II study . Patients receive oral sorafenib tosylate twice daily day 1-28 ( day 8-28 course 1 ) oral temozolomide daily day 1-7 15-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients accessible tumor ( cutaneous sub-cutaneous ) undergo biopsy baseline day 28 analysis BRAF mutation MGMT expression .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis unresectable metastatic melanoma Stage III IV disease Previously treat untreated metastatic disease At least one unidimensionally measurable lesion RECIST criterion scan MRI No concurrent brain CNS metastases PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy ≥ 3 month ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin &gt; 9 g/dL PT , INR , PTT &lt; 1.5 time upper limit normal ( ULN ) Transaminases &lt; 2.5 time ULN ( &lt; 5 case liver metastasis ) Amylase lipase &lt; 1.5 time ULN Bilirubin ≤ 1.5 time ULN Serum creatinine &lt; 1.5 time ULN Normal respiratory , cardiac , neurological function Not pregnant nursing No history follow cardiac condition : NYHA class IIIV heart failure Coronary disease Myocardial infarction within past 6 month Cardiac arrhythmia require treatment something betablockers digoxin Severe uncontrolled hypertension No severe active infection &gt; grade 2 No epilepsy require medical treatment No cancer except carcinoma situ cervix , basal cell carcinoma , superficial bladder tumor , curatively treated cancer &gt; 3 year ago No HIV hepatitis B C positivity No lactase galactokinase deficiency , galactose intolerance , disease accompany malabsorption glucose galactose No allergy study drug dacarbazine Able swallow medication No patient deprive liberty No psychological , familial , social , geographic condition would preclude clinical follow PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior organ transplantation No prior temozolomide sorafenib tosylate More 30 day since prior antitumor chemotherapy , immunotherapy , hormonal therapy , investigational agent More 30 day since prior study drug More 3 week since prior radiotherapy More 3 week since prior biological response modifier ( i.e. , filgrastim [ GCSF ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>